2015
Dec 30
Research and Development Center Vice General Manager, Peng Wenjun, representing UBIP, was honored to be received by the President, who commended the company's achievements in new drug development and brand management.
Dec 25
The Phase I clinical trial report of human erythropoietin UB-851 has been approved by the Ministry of Health and Welfare for archival purposes.
Dec 22
Human erythropoietin UB-851 has entered Phase III clinical trials.
Nov 17
UBIP has obtained regulatory approval for its initial public offering.
Oct 28
Received the National Brand Yushan Award, Outstanding Enterprise Award, and National First Prize.
Jul 28
The Phase III clinical trial of human erythropoietin UB-851 has been submitted for review.
Jun 23
Obtained the Certificate of Good Manufacturing Practice for Medicinal Products (PIC/S GMP Certificate).
May 28
The Taiwan Food and Drug Administration (TFDA) has approved the renaming of UBIP Hsinchu Plant 2 to Lianya Hsinchu Plant with a letter of record.
May 8
Obtained the Manufacturing and Sales License for Pharmaceutical Manufacturers.
Apr 30
The biosimilar drug for human erythropoietin UB-851 has completed Phase I clinical trials.
Jan 27
Taiwan Biomedical Technology Corporation Limited has invested and become a key strategic partner.
Jan 23
Factory registration obtained.